Multiple sclerosis is an often devastating disease for patients and their families. With the recent emergence of potential disease modifying therapies, early and correct diagnosis is the new cornerstone for standard-of-care, as well as the new baseline from which hope has grown for 1) effective treatments; and 2) quality of life maintenance. Central in this effort is appreciation of clinical, environment and genetic, and paraclinical prognostic indicators with a focused appreciation for what magnetic resonance imaging is bringing to this effort. But MS care is more than just a correct and timely diagnosis, it includes the need for a multidisciplinary team of physicians and other health care personnel who collectively optimize the outcome for each individual patient. As such, educational and practice needs have been identified that are addressed in this initial series of modules, written and reviewed by global faculty.
With this as backdrop, the Global Multiple Sclerosis Academy is pleased to present this e-learning module entitled “Mechanisms of Action and Long-term Benefit of Immunomodulators in Multiple Sclerosis.” This module addresses for the participant mechanisms of action of a wide range of agents used in the management of multiple sclerosis, from the classical agents interferon-beta and glatiramer acetate, through use of alemtuzumab and daclizumab. Their critical value in the treatment of multiple sclerosis is discussed in depth